PROTID

PROTID is part of the second European and Developing Countries Clinical Trial Partnership (EDCTP), which is supported by the European Union... The PROTID consortium is a network of scientists and clinicians from institutes in the Netherlands, Uganda, Tanzania, United Kingdom and New Zealand... PROTID aims to enrol 6000 people living with diabetes in Tanzania and Uganda in a large descriptive cohort, of which 3000 people with diabetes and LTBI will be randomised to a 12-week course of rifapentine and isoniazid preventive therapy or placebo, with cumulative incidence of TB disease over 24 months' follow-up as the primary endpoint. 1000 people with diabetes but without evidence of LTBI will be followed in parallel to confirm whether their incidence of TB is too low to warrant preventive treatment.